These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 30394872)

  • 1. Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains.
    Iwona BO; Karol P; Kamila CC; Pollak A; Hanna B; Agnieszka P; Andrzej H; Kosińska J; Płoski R; Tomasz L; Marek R
    J Gen Virol; 2018 Dec; 99(12):1633-1642. PubMed ID: 30394872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of 5' Untranslated Region of Hepatitis C Virus in Search of Minor Viral Variant in a Patient Who Revealed New Genotype While on Antiviral Treatment.
    Caraballo Cortes K; Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Płoski R; Lechowicz U; Stawiński P; Demkow U; Laskus T; Radkowski M
    Adv Exp Med Biol; 2016; 885():11-23. PubMed ID: 26747069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
    Kurbanov F; Tanaka Y; Matsuura K; Sugauchi F; Elkady A; Khan A; Hasegawa I; Ohno T; Tokuda H; Mizokami M
    J Infect Dis; 2010 Jun; 201(11):1663-71. PubMed ID: 20420509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
    Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
    PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.
    Lee JH; von Wagner M; Roth WK; Teuber G; Sarrazin C; Zeuzem S
    J Hepatol; 1998 Jul; 29(1):29-35. PubMed ID: 9696489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Salmerón J; Casado J; Rueda PM; Lafuente V; Diago M; Romero-Gómez M; Palacios A; León J; Gila A; Quiles R; Rodriguez L; Ruiz-Extremera A
    J Clin Virol; 2008 Apr; 41(4):264-9. PubMed ID: 18221912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Clin Virol; 2010 Mar; 47(3):258-62. PubMed ID: 20116330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
    J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
    Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
    Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.
    Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR
    J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
    Hu Z; Liu Y; Qiu L; Fan Z; Nie W; Liang S; Jin R
    Virol J; 2015 Dec; 12():220. PubMed ID: 26684004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.